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Parkinson disease (PD) is a common neurodegenerative disorder characterized by bradykinesia, resting tremor,
muscular rigidity, and postural instability, as well as by a clinically significant response to treatment with levodopa.
Mutations in the a-synuclein gene have been found to result in autosomal dominant PD, and mutations in the
parkin gene produce autosomal recessive juvenile-onset PD. We have studied 203 sibling pairs with PD who were
evaluated by a rigorous neurological assessment based on (a) inclusion criteria consisting of clinical features highly
associated with autopsy-confirmed PD and (b) exclusion criteria highly associated with other, non-PD pathological
diagnoses. Families with positive LOD scores for a marker in an intron of the parkin gene were prioritized for
parkin-gene testing, and mutations in the parkin gene were identified in 22 families. To reduce genetic heterogeneity,
these families were not included in subsequent genome-screen analysis. Thus, a total of 160 multiplex families
without evidence of a parkin mutation were used in multipoint nonparametric linkage analysis to identify PD-
susceptibility genes. Two models of PD affection status were considered: model I included only those individuals
with a more stringent diagnosis of verified PD (96 sibling pairs from 90 families), whereas model II included all
examined individuals as affected, regardless of their final diagnostic classification (170 sibling pairs from 160
families). Under model I, the highest LOD scores were observed on chromosome X (LOD score 2.1) and on
chromosome 2 (LOD score 1.9). Analyses performed with all available sibling pairs (model II) found even greater
evidence of linkage to chromosome X (LOD score 2.7) and to chromosome 2 (LOD score 2.5). Evidence of linkage
was also found to chromosomes 4, 5, and 13 (LOD scores 11.5). Our findings are consistent with those of other
linkage studies that have reported linkage to chromosomes 5 and X.
Introduction
Parkinson disease (PD [MIM 168600]) is a common
neurodegenerative disorder affecting 11% of 55-year-
old individuals and 13% of those 175 years of age (de
Rijk et al. 1997). It is characterized by bradykinesia,
resting tremor, muscular rigidity, and postural instability,
as well as by a clinically significant response to treatment
with levodopa (Gasser 2001). The pathology of PD in-
volves the degeneration of brain dopaminergic path-
ways, mostly in the substantia nigra but also in other
regions of the brain, and the presence of Lewy bodies
in the substantia nigra (Gibb and Lees 1989; Fearnley
and Lees 1991).
To better understand the role of genetics in PD, many
investigators have initiated studies to estimate familial
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aggregation of PD in first- and/or second-degree rela-
tives of patients with PD. Studies around the world have
provided evidence that genetic risk factors are involved
in the pathogenesis of the idiopathic form of PD. Es-
timates of the relative risk to first-degree relatives of an
affected individual range from 2.7 (Kuopio et al. 2001)
to 3.5 (Payami et al. 1994) in the United States and are
2.9 in Finland (Autere et al. 2000), 6.7 in Iceland (Svein-
bjornsdottir et al. 2000), 7.7 in France (Preux et al.
2000), 3.2 in three centers within Europe (Elbaz et al.
1999), 5.0 in Canada (Uitti et al. 1997), 13.4 in Italy
(De Michele et al. 1995), and 7.1 in Germany (Vieregge
et al. 1994).
Several families with Mendelian segregation of PD
have been reported. At present, four genes implicated
in autosomal dominant forms of parkinsonism have
been identified or localized. The alpha-synuclein gene
was identified by studying a large Italian kindred in
which PD was pathologically confirmed (Polymeropou-
los et al. 1997). The same alpha-synuclein mutation,
G209A, observed in the Italian kindred was later found
in three Greek families, most of which can trace their
ancestry to a very small geographical area on the Pelo-
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ponnisos in southern Greece (Polymeropoulos et al.
1997). Alpha-synuclein mutations in eight additional
individuals from six different families from central and
southwestern Greece have been reported more recently
(Bostantjopoulou et al. 2001). In view of the close his-
torical ties to southern Italy, these mutation results sug-
gest the presence of a founder effect (Gasser 2001). Sub-
sequently, another mutation, G88C, in the gene was
identified in a German family with autosomal PD (Kru-
ger et al. 1998). But, since no other mutations in alpha-
synuclein have been identified in the large number of
patients with sporadic or familial PD that have been
screened (Chan et al. 1998; Farrer et al. 1998; Vaughan
et al. 1998; Pastor et al. 2001), alpha-synuclein is most
likely not a major risk factor in familial PD. Amutation,
Ile93Met, in the ubiquitin carboxy-terminal hydrolase-
L1 gene was identified in two individuals with PD who
were members of a German pedigree (Leroy et al. 1998).
The PARK3 locus on chromosome 2p13 has been linked
in a subset of families with German ancestry (Gasser et
al. 1998), although the responsible gene has not yet been
identified. Last, the PARK4 locus on chromosome 4p14-
16.3 has been linked in a four-generation pedigree (Far-
rer et al. 1999). Despite these promising findings, ped-
igrees with autosomal dominant PD are rare and seem
to represent only a small number of families with PD
(The French Parkinson’s Disease Genetics Study Group
1998).
Autosomal recessive juvenile parkinsonism (ARJP
[MIM 600116]) is a distinct clinical and genetic entity
within familial PD. It is characterized by typical PD
features and an early (!40 years) age at onset, slow
progression of the disease, sustained response to levo-
dopa, early levodopa-induced complications (fluctua-
tions and dyskinesias) that are often severe, hyperre-
flexia, and mild dystonia, mainly in the feet (Yamamura
et al. 1973; Ishikawa and Tsuji 1996). Among the genes
implicated in familial PD, the largest number of mu-
tations have been found in the parkin gene (Kitada et
al. 1998), and mutations in this gene might account for
PD in as many as 50% of familial patients with ARJP
(Lu¨cking et al. 2000). Two other loci have been impli-
cated in autosomal recessive early-onset parkinsonism:
PARK6 has been localized on chromosome 1p35-36 in
a single Italian family (Valente et al. 2001), and PARK7
has been mapped to chromosome 1p37 in a consan-
guineous pedigree from a genetically isolated popula-
tion in the southwestern region of the Netherlands (van
Duijn et al. 2001).
There is clear evidence of a single Mendelian gene in
a minority of families with PD. However, evidence of
a genetic contribution to more typical, late-onset PD
has not been universal. A report of a low concordance
rate of PD in a sample of World War II veteran twins
has been interpreted to imply that the role of genes in
PD susceptibility is minimal. Further analyses of these
data suggest greater twin concordance among twins
with early-onset PD (Tanner et al. 1999). A major lim-
itation of most twin studies is that they are usually cross-
sectional in nature. In the case of PD, in which the age
at onset is quite variable, a cross-sectional study may
fail to identify concordant twin pairs with widely dif-
fering ages at onset. In one instance, the age at onset
of PD in a pair of MZ twins differed by 20 years (Dick-
son et al. 2001). Functional imaging of the brain has
suggested that some apparently normal cotwins actually
have decreased function of the nigrostriatal dopami-
nergic system and may be presymptomatic, implying
that the concordance rates for both MZ and DZ twins
may be higher than previously estimated (Burn et al.
1992; Piccini et al. 1997).
The purpose of the present study was to identify genes
contributing to PD susceptibility, particularly among
families with more typical, later-onset PD. Since, to
date, mutations in parkin are the most common inher-
ited defect identified in PD, our initial efforts were fo-
cused on identifying those families likely to have parkin
mutations, so that they could be further screened and
eliminated from the genome-screen analyses. Our in-
tention was to reduce the genetic heterogeneity in our
sample and, thereby, to increase our power to detect
non-parkin PD-susceptibility genes. Our study provides
evidence of PD-susceptibility loci in several chromo-
somal regions.
Subjects and Methods
Subjects
Families consisting of at least one pair of living sib-
lings diagnosed with PD were recruited through 60 Par-
kinson Study Group (PSG) sites located throughout
North America. The sample was primarily white (94%),
although Hispanics (6%) also participated. All study
participants completed a uniform clinical evaluation that
consisted of parts II and III of the Unified Parkinson
Disease Rating Scale (Lang and Fahn 1989). A diag-
nostic checklist also was completed by a PSGmovement-
disorder specialist, with inclusion criteria consisting of
clinical features highly associated with autopsy-con-
firmed PD and with exclusion criteria highly associated
with other, non-PD pathological diagnoses (see the Ap-
pendix) (Hughes et al. 1992a, 1992b). Responses on the
diagnostic checklist were then used to classify study sub-
jects as having verified PD (285 subjects) or nonverified
PD (99 subjects). Peripheral blood was obtained from
all individuals after appropriate written informed con-
sent approved by each individual institution’s institu-
tional review board was completed. DNA was prepared
by standard methods (Madisen et al. 1987).
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Table 1
Demographics of Sample
MODEL
NO. OF
% MALE
MEAN  SD AGE AT ONSET
(years)Families Pairs
I (183 subjects) 90 96 60 62.3  9.7 (range 32–83)
II (325 subjects) 160 170 61 62.8  10.7 (range 18–83)
One of the advantages of our study is the use of the
diagnostic checklist for the classification of disease
status. The inclusion criteria, consisting of clinical fea-
tures highly associated with autopsy-confirmed PD, in
conjunction with the exclusion criteria, consisting of
clinical features highly associated with other, non-PD
pathological diagnoses, provide the stringent diagnostic
criteria essential for the successful identification of PD-
susceptibility genes. The high interrater and intersite re-
liability of the diagnostic instrument provided further
reassurance that error in diagnosis was kept at a mini-
mum (Siemers et al. 1998).
parkin Screening
A marker (D6S305) in intron 7 of the parkin gene
was genotyped in all study subjects. Families with pos-
itive LOD scores at this marker, under an autosomal
recessive model of disease inheritance ( ), andnp 68
families with an affected family member with an age at
onset of !45 years ( ) were screened for parkinnp 21
mutations, by both direct-sequencing and fluorescent-
dosage analysis (Nichols et al., in press). Twenty differ-
ent parkin mutations were identified in 22 of the 74
families analyzed. Genetic analyses were performedwith
and without the families with a parkin mutation.
Genotyping
A genome screen was completed by use of 400 dinu-
cleotide markers, from the ABI Prism Linkage Mapping
Set (Applied Biosystems), that had an average hetero-
zygosity of 79% and an average intermarker spacing of
8.6 cM. The average information content for the 23 chro-
mosomes was 0.65 when estimated every 1 cM and was
0.71 when estimated at a marker (Mapmaker/Sibs; Krug-
lyak and Lander 1995). In brief, 30 ng of genomic DNA
was PCR amplified by use of each marker, in a 10-ml
reaction. After PCR, the PCR products were pooled by
use of equal amounts of each PCR. One microliter of this
multiplexed mix was added to 10 ml of formamide con-
taining the GENESCAN-400HDROX size standard (Ap-
plied Biosystems). Genotypes were determined by an ABI
3700 DNA Analyzer (Applied Biosystems) and GENE-
SCAN 3.5, GENOTYPER 3.6, and GENEMAPPER 1.1
software.
All genotypic data were evaluated for Mendelian in-
heritance of marker alleles, by the program Pedcheck
(O’Connell and Weeks 1998). The marker genotypic
data were used to verify the full-sibling relationships
among the subjects, by the computer program RELA-
TIVE (Goring and Ott 1997). Three half-sibling pairs
were eliminated from further analyses, because the shar-
ing of marker alleles identical by descent was signifi-
cantly lower than that which would be expected for full
siblings.
Statistical Analysis
A total of 160 families ( individuals) who hadnp 325
no evidence of a parkin mutation and who had two or
more affected siblings were available for genetic anal-
yses. Of the two models of affection considered for this
sample, model I included only those individuals with a
more stringent diagnosis of verified PD ( siblingnp 96
pairs, from 90 families), whereas model II included all
examined individuals as affected, regardless of their final
diagnostic classification ( sibling pairs, fromnp 170
160 families). The majority of families consisted of a
single pair of affected siblings. Under model I, there were
87 families with a single affected sibling pair and 3 fam-
ilies with three affected siblings. Under the broader dis-
ease definition employed in model II, there were 155
families with two affected siblings and 5 families with
three affected siblings. The average age at onset of PD
did not differ significantly ( ) between the samplePp .47
employed in the model I analyses and the sample of
individuals included in the more inclusive model II def-
inition. The characteristics of the study population are
listed in table 1.
Multipoint nonparametric linkage analysis was per-
formed for both models of affection status, by the max-
imum-likelihood method implemented in the computer
program Mapmaker/SIBS (Kruglyak and Lander 1995).
Analysis was performed both with dominance variance
fixed at zero and with dominance variance free to vary.
Analyses were performed by employing all possible sib-
ling pairs from families of size greater than two.
For completeness, genomewide linkage analyses also
were performed with the entire collected sample, includ-
ing those families with a known parkin mutation (np
families). In addition, to identify any potential loci182
acting epistatically with the parkin gene, a genomewide
linkage analysis also was performed in a sample limited
to the 22 families with a known parkin mutation.
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Figure 1 Multipoint LOD-score graph summarizing results of genome screen of chromosomes 1–22 and X, under the narrower, model
I definition of PD diagnosis.
Results
Results of the genome screen of the families with par-
kin mutations were reviewed ( families), andnp 160
chromosomal regions with LOD scores 11.5 were iden-
tified for further evaluation (figs. 1 and 2 and table 2).
Information content, both at linked markers and in the
linked intermarker regions, was comparable to that ob-
served in the full genome. When only PD sibling pairs
meeting the stricter PD diagnostic criteria were includ-
ed in the analyses (model I), three chromosomal re-
gions had LOD scores 11.5 (fig. 1). The highest LOD
scores were observed on chromosome X (LOD score
2.1), near marker DXS1001 (fig. 3), and on chromosome
2 (LOD score 1.9), near marker D2S206 (fig. 4). Three
markers in this 21-cM region on chromosome X (i.e.,
markers DXS1106, DXS8055, and DXS1001) yielded
LOD scores 11.5. Subsequent analyses suggested that
the majority of the evidence of linkage to this region is
derived from 35 brother-brother pairs (LOD score 1.8).
Analyses of the 17 sister-sister pairs produced a maxi-
mum LOD score of 0.9 in this region of Xq. Linkage
analyses employing the mixed-sex sibships ( sibnp 44
pairs) yielded a maximum LOD score of 0.3. In addition,
a LOD score of 1.6 was found for chromosome 5, near
marker D5S471.
Analyses were also performed with all available sibling
pairs (model II). With this larger sample of sibling pairs,
LOD scores 11.5 were observed for chromosomes 2, 4,
13, and X (table 2 and fig. 2). The maximum LOD score
obtained for the entire genome screen was for chromo-
some X (LOD score 2.7), near marker DXS1106 (fig. 3).
Three markers in this 23-cM region (i.e., markers
DXS1106, DXS8055, and DXS1001) yielded LOD
scores 11.5. Subsequent analyses suggest that the major-
ity of the evidence of linkage to this region is derived
from 66 brother-brother pairs (LOD score 1.9). Analyses
of the 29 sister-sister pairs produced a maximum LOD
score of 0.65 for this region of Xq. Linkage analyses
employing the mixed-sex sibships ( sib pairs)np 75
yielded a maximum LOD score of 0.24.
The maximum LOD score for chromosome 2, when
the broader disease definition (model II) was used, was
2.5. Similar to what was seen in the model I analyses,
the maximum LOD score for chromosome 2 was near
marker D2S206 (fig. 4). Three markers in this region of
chromosome 2, spanning 24 cM, produced LOD scores
1.5 (i.e., D2S396, D2S206, and D2S338). Thus, the
two chromosomes with the highest LOD scores under
themore restrictivemodel I diagnosis also had the highest
LOD scores under the broader disease definition.
Two additional chromosomal regions had LOD
scores above our initial threshold of 1.5. A maximum
LOD score of 1.6 was found for chromosome 4, near
marker D4S1597, and a maximum LOD score of 1.5
was found for chromosome 13, near marker D13S171.
Linkage analyses also were performed in the entire
collected sample ( families), including the 22np 182
families with an identified parkinmutation (table 2). For
chromosomes 4, 5, and X, both the LOD score under
both model I and that under model II were lower than
those for the analyses performed without families with
parkin mutations. For chromosome 13, the complete
sample had a higher LOD score under model II only
(LOD score 2.1 vs. LOD score 1.5). Analyses performed
with the entire sample did identify one additional chro-
mosomal region, on chromosome 10 (LOD score 1.6),
that met our initial linkage threshold. Interestingly, for
chromosome 2, the entire sample produced a substan-
tially higher LOD score under model I (LOD score 3.1
vs. LOD score 1.9). To further examine the potential role
of a PD-susceptibility locus on chromosome 2, as well
as potential epistatic interactions between parkin and
other loci, a genome screen was performed with only the
22 families with parkin mutations (fig. 5). In this small
subset of the data, there was no evidence of a PD-sus-
ceptibility gene on chromosome 2; however, there was
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Table 2
Regions with LOD Scores 1.5
CHROMOSOME
POSITIONa
(cM)
LOD SCORE
With Families
with parkin
Mutations
Without Families
with parkin
Mutations
Model I Model II Model I Model II
2 236 3.1 2.5 1.9 2.5
4 160 1.1 1.4 1.4 1.6
5 128 1.3 .7 1.6 .5
10 68 .6 1.6 .6 1.3
13 13-22 1.2 2.1 1.3 1.5
X 105-122 1.4 2.5 2.1 2.7
a Based on the sex-averaged genetic maps from the Center for Med-
ical Genetics, Marshfield Medical Research Foundation.
Figure 2 Multipoint LOD-score graph summarizing results of genome screen of chromosomes 1–22 and X, under the broader, model II
definition of PD diagnosis.
some evidence of linkage to chromosomes 8 (LOD score
1.6), 12 (LOD score 2.0), and 19 (LOD score 1.7).
Discussion
Three other studies are currently ongoing that seek to
identify PD-susceptibility genes. The GenePD study, an-
alyzing data from 113 sibling pairs, has reported LOD
scores of 0.9–1.3 for chromosomes 1, 9, 10, and 15
(DeStefano et al. 2001). A second study, analyzing 174
extended pedigrees, including 378 affected individuals,
has reported LOD scores of 1.5–2.5 for chromosomes
5, 8, 9, 14, 17, and X in families with late-onset PD
(Scott et al. 2001). The deCODE study in Iceland has
reported a LOD score of 4.9 on chromosome 1, as well
as evidence of linkage to chromosomes 5, 7, 13, 14, and
X (Hicks et al. 2001).
We have completed a genome screen in a large sam-
ple of 170 sibling pairs with PD that were ascertained
from 160 families. Unlike previous PD-linkage stud-
ies, ours has attempted to reduce genetic heterogeneity
by screening all families by use of a marker in the parkin
gene, to identify families likely to have parkin muta-
tions. This has allowed us to identify 22 families with
parkin mutations who were then removed from sub-
sequent genome-screen analyses. Linkage analyses per-
formed with and without the families with parkin mu-
tations suggest that most of the LOD scores that we
have reported increased with the removal of the families
with known parkin mutations (table 2).
In this study, the strongest evidence of linkage was
reported for chromosome X. Evidence of linkage was
observed both under the more restrictive (model I) and
under the broader (model II) disease definitions. The
maximum LOD score in each analysis was at a different
marker; however, these markers are only 13 cM apart
and likely represent the same underlying susceptibility
gene. It is interesting that, in our sample, most of the
evidence of linkage to this region on chromosome X
came from the brother-brother pairs. It is intriguing to
speculate that this linkage to chromosome X might ex-
plain the slightly higher incidence of PD among males
(Tanner et al. 1992).
Two other PD studies appear to report linkage to this
same region of Xq21-25 (Hicks et al. 2001; Scott et al.
2001). Unfortunately, few details were provided, in either
study, regarding the markers near the maximum LOD
score. Also, neither study reported whether the evidence
of linkage was limited to a sample subset consisting of
brother pairs, as is the case in our study. Thus, it is dif-
ficult to verify whether the results from these other studies
might represent converging lines of evidence supporting
the presence of a PD-susceptibility gene on chromosome
X.
Interestingly, X-linked dystonia parkinsonism (XDP),
which has been reported at high incidence in Panay, The
Philippines, has been linked to Xq13.1 (Lee et al. 2001).
It is an adult-onset, highly penetrant, X-linked disorder
that primarily afflicts men (male:female ratio 123:1). It
is a severe, progressive disorder with onset typically oc-
curring, with dystonic movements, during the 3rd or 4th
decade. Approximately a decade after disease onset, the
dystonia typically coexists or is replaced by parkinson-
ism. Neuropathology reveals pronounced atrophy of the
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Figure 3 Multipoint LOD-score graph of chromosome X, under
models I (dashed line) and II (solid line).
caudate and putamen, mostly in the cases with long-
standing illness (Lee et al. 2001). The gene has been
mapped to an !350-kb region in the DXS7117–DXS559
region (Nemeth et al. 1999), !20 cM from the region
identified in our study. Our linkage finding may seem to
be too far from the XDP linkage to represent the same
gene. However, when, in our entire sample (np 182
families), we review the data for chromosome 6, we find
that the maximum LOD score (LOD score 1.1) occurs
∼25 cM proximal to the actual location of the parkin
gene. This is the case even when a marker is genotyped
in exon 7 of the parkin gene. Thus, we believe that the
XDP gene remains a possible positional candidate gene.
We have used complementary methods of analysis to
ensure maximum power to detect loci contributing to
PD susceptibility. Holmans (1993) has shown that anal-
ysis of affected-sib-pair data under the assumption of
dominance variance, when Holmans’s “possible trian-
gle” is applied, appears to allow for a more sensitive
test for putative genes acting in a recessive fashion than
does analysis when dominance variance is fixed at zero.
Several studies have reported higher estimates of relative
risk for PD among siblings of affected individuals, com-
pared with the risk of PD among the parents or offspring
of affected individuals (Autere et al. 2000; Sveinbjorns-
dottir et al. 2000), suggesting evidence of at least some
recessively acting PD-susceptibility genes. This would
appear to be supported both by the recessively acting
genes already implicated, such as parkin, and by the
recent linkage findings on chromosome 1 (Vallente et
al. 2001; van Duijn et al. 2001). We also have observed
empirical data suggesting that LOD scores at a reces-
sively acting locus increase when dominance variance
is free to vary. Before the families with parkinmutations
were removed, the LOD score for the parkin locus in
the entire sample increased from 0.6 to 1.1 when dom-
inance variance was free to vary; likewise, when the
sample was limited to only the 22 families with parkin
mutations, the LOD score increased from 5.0 to 7.6
(fig. 5).
In our study, the linkage findings for chromosome 2q
are consistent with a recessively acting susceptibility lo-
cus. Allowing the dominance variance to vary increased
the LOD score from 1.2 to 1.9 under model I and from
2.1 to 2.5 under model II. The linkage finding in this
region was supported by three markers, all with LOD
scores 11.5. None of the other three genomewide link-
age studies (DeStefano et al. 2001; Hicks et al. 2001;
Scott et al. 2001) have reported any evidence of linkage
to chromosome 2.
The linkage to chromosome 4q32 was supported by
four markers with a LOD score 11.0. In addition, an-
other region, ∼70 cM away, at 4q21, had a maximum
LOD score of 1.1. None of the other three studies have
reported linkage to either region (DeStefano et al. 2001;
Hicks et al. 2001; Scott et al. 2001). The strongest can-
didate gene in this region is alpha-synuclein, which is
near marker D4S1534 in the 4q21 region. Although
only a few families with mutations in the alpha-synu-
clein gene have been identified (Chan et al. 1998; Farrer
et al. 1998; Vaughan et al. 1998; Pastor et al. 2001),
several recent studies have reported an association be-
tween PD and haplotypes in the promoter region of the
alpha-synuclein gene (Kruger et al. 1999; Farrer et al.
2001b).
The evidence of linkage to chromosome 5q23 is sup-
ported by four markers with a LOD score 11.0. Similar
to the linkage finding on chromosome 2, the results of
analyses performed on chromosome 5, under model I,
suggest that this locus also may be a recessively acting
susceptibility locus; the maximum LOD score increased
from 0.9 to 1.6 when linkage analyses were performed
with dominance variance allowed to vary. Unlike the
other linkage findings reported in this study, for this re-
gion there is a large disparity between the maximum
LOD score under model I and that under model II. The
higher LOD scores under model I may provide insight
with regard to the putative gene’s mode of action. “Par-
kinsonism” is a term referring to all clinical states char-
acterized by tremor, muscle rigidity, and slowed move-
ment (termed “bradykinesia”) (Koller and Hubble 1992)
and includes secondary forms of parkinsonism, such as
those resulting from drug exposure and stroke. PD is the
most common form of parkinsonism. We anticipate that
model II includes some subjects with parkinsonism but
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Figure 4 Multipoint-LOD-score graph of chromosome 2, under model I (dashed line) and II (solid line)
without PD. Perhaps the 5q23 locus is a PD-specific sus-
ceptibility locus, whereas most of the other loci mapped
in this study may confer more-general parkinsonism sus-
ceptibility. Alternatively, the same genes may be contrib-
uting to both model I and model II; however, analyses
performed with the broader disease model (i.e., model
II) may result in higher LOD scores simply because the
sample size is greater, as is the power to detect genetic
effects.
Two other studies have reported linkage to 5q23
(Hicks et al. 2001; Scott et al. 2001). Scott et al. re-
ported a multipoint LOD score of 1.5 for marker
D5S816, which is !10 cM from marker D5S471, where
the maximum LOD score was found. Within this cy-
togenetic band is a gene that is an excellent potential
candidate, the synphilin-1 gene (SNCAIP). Normal par-
kin ubiquitinates synphilin-1 as well as the glycosylated
form of alpha-synuclein. It is proposed that, without
proper ubiquitination, these molecules do not properly
degrade and that the accumulation of these proteins
thus becomes toxic. Notably, all three of these proteins
are present in the intracytoplasmic inclusions called
“Lewy bodies” (Chung et al. 2001). No mutations in
SNCAIP have been discovered in a small sample of pa-
tients with PD who have been screened in other studies
(Bandopadhyay et al. 2001; Farrer et al. 2001a).
Linkage near the centromere of chromosome 13 is sup-
ported by two markers with LOD scores 11.0. Hicks et
al. (2001) have reported linkage near this region, al-
though the exact position and magnitude of their link-
age finding has not been reported. One attractive can-
didate gene in this region is the copper-transporting
P-type ATPase gene (ATP7B), which, if mutated, results
in the autosomal recessive disorder Wilson disease. Cox
et al. (1972) referred to the two“typical” forms ofWilson
disease as being the “Slavic” type and the “juvenile” type,
with the latter being a differential diagnosis considered
for patients presenting with early-onset parkinsonism.
The Slavic type has a late age at onset and is predomi-
nantly a neurologic disease that, like PD, affects the basal
ganglia and can manifest tremor, dysarthria, poor motor
coordination, and dementia. Approximately 1% of the
general population are thought to be carriers of Wilson
disease (Riordan and Williams 2001). These individuals
typically do not have any clinical sequelae; however, they
do have problems with copper metabolism. This is sig-
nificant, because copper concentration in the cerebro-
spinal fluid has been reported at significantly increased
levels in patients with idiopathic PD, compared with that
in control subjects (Pall et al. 1987). Furthermore, al-
pha-synuclein has been shown to undergo self-oligomer-
ization in the presence of copper(II) (Paik et al. 2000;
Kim et al. 2001; Uversky et al. 2001), which may lead
to the protein aggregation and neurodegeneration found
in both PD and Alzheimer disease.
Similar to studies of other complex genetic disorders,
previous genetic studies of PD have reported several link-
age findings that were not replicated in our study. Most
notable is the linkage to chromosome 1, reported by
Hicks et al. (2001), in a sample of 117 affected individ-
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Figure 5 Multipoint LOD-score graph summarizing results of genome screen of chromosomes 1–22 and X, for the 22 families with parkin
mutations.
uals from the genetically isolated population of Iceland.
In that study, the result for chromosome 1 was the most
significant linkage result, with a LOD score of 4.9. How-
ever, we found no evidence of linkage to this region (LOD
score !0.6, both under model I and under model II).
Importantly, no evidence of linkage near the centromere
of chromosome 1 was reported in the two other ge-
nomewide studies of PD. It is therefore possible that a
PD-susceptibility gene on chromosome 1 is present at
high frequency only in the Icelandic population.
The study by Scott et al. (2001) found the most sig-
nificant linkage on chromosome 17, near the tau gene.
The strength of this linkage finding was increased when
analyses were limited to a subset of families in which
at least one individual in the kindred was not responsive
to levodopa treatment. Since a positive response to this
dopamine precursor is very common among individuals
with PD, Scott et al. considered this potential pheno-
typic heterogeneity to be indicative of genotypic het-
erogeneity. The most notable improvements to LOD
scores were for chromosomes 3, 9, and 17. Exploratory
analyses were performed in our sample of only nine
families, containing 11 sibling pairs, in which at least
one member of the family was not responsive to levo-
dopa. In this very small data set as well, as in analyses
performed with either model I or model II, we found
no evidence of linkage to tau (LOD scores 0.2, 0.0, and
0.0, respectively). Unlike our study of a sample pri-
marily comprising sibling pairs, the study by Scott et
al. (2001) included many extended pedigrees. Thus, it
is possible that some of the families in that study are
segregating a mutation in tau, which might produce an
autosomal dominant pattern of PD inheritance.
In our sample of 170 affected sibling pairs, we have
identified two chromosomal regions with particularly
strong evidence of linkage. The findings for chromo-
somes 2 and X suggest the presence of loci that con-
tribute to PD susceptibility, both in our analysis em-
ploying a narrow disease definition and in our analysis
employing a more broader disease classification. These
findings may suggest loci contributing to parkinsonism
susceptibility—rather than simply to PD susceptibility
per se. Importantly, our study has provided additional
evidence of linkage, in an independent sample, to chro-
mosomes 5 and X. We are continuing to recruit families
with multiple living members diagnosed with PD, to
replicate the results found for chromosomal regions
identified in these analyses. An important advantage of
our study is the identification and removal, prior to the
genome-screen analyses, of families with parkin muta-
tions. This has reduced genetic heterogeneity in our
sample and, in most instances, has increased the LOD
score for linked chromosomal regions.
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Appendix
Inclusion and Exclusion Criteria
Inclusion Criteria
Age at onset 120 years
Bradykinesia
Clinician’s overall impression that the subject has PD is 150%
At least one of the following:
Muscular rigidity
Rest tremor
Postural instability
At least two of the following:
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Persistent asymmetry of signs
Progressive disorder
Rest tremor
150% Levodopa response
Levodopa-induced chorea
Levadopa response for 5 years
Clinical course of 10 years
Exclusion Criteria
Unexplained upper motor-neuron signs
History of repeated strokes with stepwise progression of parkinsonian features
History of encephalitis
History of oculogyric crisis
Clinical features/course suggesting Alzheimer disease or other dementia distinct from PD
Cortical sensory deficits or apraxia
Parkinsonism likely due to antidopaminergic drug use
Sustained remission of parkinsonian symptoms
Strictly unilateral features after 3 years
Supranuclear gaze palsy with down gaze !50% of normal
Cerebellar signs
Symptomatic orthostatic hypotension early in the course of the disease
Failure to respond to large dosage of levodopa
Brain imaging (by computed tomography or magnetic-resonance imaging) reveals presence of structural lesion(s)
likely causing or contributing to parkinsonism
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Center for Medical Genetics, Marshfield Medical Research
Foundation, http://research.marshfieldclinic.org/genetics/
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for PD [MIM 168600] and ARJP
[MIM 600116])
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